-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new dosage form of domestically-made bivalent HPV vaccine-prefilled syringes has been launched in Guangzhou recently
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
Human papillomavirus is abbreviated as HPV, which is the main cause of cervical cancer
.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
The "Guidelines for Comprehensive Prevention and Control of Cervical Cancer" mentions that the first line of defense for cervical cancer is HPV vaccination, which can reduce HPV infection
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
Yi Danni said that the current types of cervical cancer vaccines include domestically produced bivalent, imported bivalent, quadrivalent, and nine-valent vaccines
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
According to the Guangzhou hospital Qin Luo positive branch president assistant introduced recently on-line domestic bivalent HPV vaccine increases the pre-filled forms, improve the seeding efficiency, reduce secondary pollution inoculation process, "pre-filled forms The HPV vaccine comes with a syringe needle, which can be directly vaccinated.
It is more convenient and faster to operate than a vial and has higher safety
.
"
It is more convenient and faster to operate than a vial and has higher safety
.
"
In recent years, the global supply of HPV vaccines has been insufficient, especially high-priced vaccines.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
The World Health Organization (WHO) global strategy to eliminate cervical cancer calls for at least 90% of girls to complete HPV vaccination before the age of 15
.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
Recently, the domestic bivalent HPV vaccine has passed the pre-certification of the World Health Organization, becoming the first domestic HPV vaccine to obtain the certification
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
A new dosage form of domestically-made bivalent HPV vaccine-prefilled syringes has been launched in Guangzhou recently
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
Human papillomavirus is abbreviated as HPV, which is the main cause of cervical cancer
.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
The "Guidelines for Comprehensive Prevention and Control of Cervical Cancer" mentions that the first line of defense for cervical cancer is HPV vaccination, which can reduce HPV infection
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
Yi Danni said that the current types of cervical cancer vaccines include domestically produced bivalent, imported bivalent, quadrivalent, and nine-valent vaccines
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
According to the Guangzhou hospital Qin Luo positive branch president assistant introduced recently on-line domestic bivalent HPV vaccine increases the pre-filled forms, improve the seeding efficiency, reduce secondary pollution inoculation process, "pre-filled forms The HPV vaccine comes with a syringe needle, which can be directly vaccinated.
It is more convenient and faster to operate than a vial and has higher safety
.
"
It is more convenient and faster to operate than a vial and has higher safety
.
"
In recent years, the global supply of HPV vaccines has been insufficient, especially high-priced vaccines.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
The World Health Organization (WHO) global strategy to eliminate cervical cancer calls for at least 90% of girls to complete HPV vaccination before the age of 15
.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
Recently, the domestic bivalent HPV vaccine has passed the pre-certification of the World Health Organization, becoming the first domestic HPV vaccine to obtain the certification
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
A new dosage form of domestically-made bivalent HPV vaccine-prefilled syringes has been launched in Guangzhou recently
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
.
Yi Danni, chief physician of the Cervical Disease Diagnosis and Treatment Center of Guangzhou Women's and Children's Medical Center, said that HPV (papilloma virus) vaccination is receiving increasing attention in China, but compared with internationally, the current domestic HPV vaccination rate is relatively low.
, "The domestic bivalent HPV vaccine is currently in sufficient supply in the market.
Women between the ages of 9 and 45 are required to be vaccinated.
The sooner they are vaccinated, the better protection they can get
.
"
Human papillomavirus is abbreviated as HPV, which is the main cause of cervical cancer
.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
Female female female female tumor tumor tumor healthy healthy healthy.
Cervical cancer is the world's women 's fourth largest malignant tumor , while the mainland is the largest gynecological malignancies
.
In recent years, the morbidity and mortality of cervical cancer in the mainland have been increasing, and there is a trend of getting younger.
Its morbidity and mortality account for almost one-sixth of the world’s total.
It is a serious threat to the health and development of women in the mainland .
Control is urgent
.
The "Guidelines for Comprehensive Prevention and Control of Cervical Cancer" mentions that the first line of defense for cervical cancer is HPV vaccination, which can reduce HPV infection
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
.
However, according to the “Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer”, data is quoted saying that the domestic HPV vaccination rate is still very low.
Three years after the HPV vaccine was approved in China, only 3.
1% of women aged 18 to 45 received the HPV vaccine
.
Yi Danni said that the current types of cervical cancer vaccines include domestically produced bivalent, imported bivalent, quadrivalent, and nine-valent vaccines
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
.
HPV16 and HPV18 are the two most risky virus strains.
For the prevention of cervical cancer, the bivalent and quadrivalent vaccines are basically the same.
Vaccination covering the above two subtypes can prevent about 84.
5% of cervical cancers.
.
According to the Guangzhou hospital Qin Luo positive branch president assistant introduced recently on-line domestic bivalent HPV vaccine increases the pre-filled forms, improve the seeding efficiency, reduce secondary pollution inoculation process, "pre-filled forms The HPV vaccine comes with a syringe needle, which can be directly vaccinated.
It is more convenient and faster to operate than a vial and has higher safety
.
"
Hospital hospital hospitalIt is more convenient and faster to operate than a vial and has higher safety
.
"
In recent years, the global supply of HPV vaccines has been insufficient, especially high-priced vaccines.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
Therefore, there is still a large market for bivalent HPV vaccines
.
According to the relevant person in charge of Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
(Wantai Canghai), the domestic bivalent HPV vaccine manufacturer, the domestic bivalent HPV vaccine market is currently in sufficient supply, and the supply has increased from 15 million units per year to 30 million.
Support
.
The World Health Organization (WHO) global strategy to eliminate cervical cancer calls for at least 90% of girls to complete HPV vaccination before the age of 15
.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
Standard Standard Standard.
Recently, the Guangdong Provincial Government plans to add about 600 million yuan for free HPV vaccination between 2022 and 2024
.
Yi Danni said that this will increase the vaccination rate, "I believe that the vaccination rate will reach international standards in the near future
.
"
Recently, the domestic bivalent HPV vaccine has passed the pre-certification of the World Health Organization, becoming the first domestic HPV vaccine to obtain the certification
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
.
According to reports, in September 2020, Wantai Bio's 9-valent HPV vaccine officially entered clinical phase III.
If it is estimated according to the general cycle of vaccine clinical trials, it will be available within 4 years
.
(over)
